No signal was created. Models could not agree on a directional bias.
- •The core tension lies between a technical short thesis focused on immediate resistance at $1104 and a fundamental long thesis betting on a dense June catalyst calendar and secular momentum to defend the $1061 support zone.
LLY is in a strong secular uptrend (+71% off 52-week low, price 11% over SMA50) and has a dense calendar of dated catalysts inside the swing window — ADA Scientific Sessions (Jun 5-8) with retatrutide car dio metabolic data and EHA (Jun 11-14) Jaypirca Phase 3 results — plus fresh commercial wins (CVS Caremark adding Zepbound/Foundayo, oral GLP-1 Foundayo approval) . A pullback to the $1061-1062 support/SMA 20 confluence offers a defined-risk long entry ahead of these data readouts, with a path back toward the $1103 1day resistance and prior $1149 high.
LLY is rejecting from the $1100-$1149 resistance zone after a failed breakout attempt, with bearish momentum divergence building across multiple timeframes. The 4h MACD has just crossed bearish (signal line crossed below zero) and the histogram is falling, while RSI on both the 1-day and 4h is declining from overbought territory. With stretched valuation (P/E 39.2, Fwd P/E 24.8) and upcoming binary catalyst risk at ADA Scientific Sessions (June 5-8) where high expectations for retatrutide data create a "buy the rumor, sell the news" dynamic, the stock is vulnerable to a mean-reversion move back toward the 4h SMA50 at $1001 and the value area low near $858.
- →A 4h close below $1052 would signal a loss of the value-area high and SMA20 confluence, confirming a breakdown toward the $1022 support level.
- →A daily close above $1104, potentially driven by positive retatrutide data at the ADA sessions (June 5-8), would confirm the current pullback as a minor dip and re-establish the primary uptrend toward $1149.
Individual Model Analysis
Bull/Bear CompetitionWinner: BEAR
LLY is rolling over from the top of its 30-day value area ( $1066.99) just below the $1103-1149 resistance zone, with the 4h MACD posting a fresh bearish zero-cross and RSI falling across all three timeframes — a near-term momentum exhaustion after a +71% run off the lows. The expected path is a fade back toward the SMA 20/value-area interior near $1027-1040 as the short-term bid weakens and the stock loses its perch on the $1061 support shelf. With a stretched 39x P/E exposed to >4.5% Treasury yields and XLV sector breadth confirming today's weakness, conditions favor a controlled pullback over the next 1-3 weeks.
LLY holds a strong daily uptrend (above SMA 20/50, positive MACD) and sits just above 1day support at $1061.62 after a normal pullback into the value-area edge. A dense June catalyst calendar — ADA Scientific Sessions (Jun 5-8) with retatrutide data, EHA (Jun 11-14) Jaypirca Phase 3, plus completed PBM coverage for Zepbound/Foundayo and the new oral GLP-1 approval — provides upside triggers within the 1-3 week swing horizon that can carry price back toward the $1103 resistance and prior $1149 high.
Bull/Bear CompetitionWinner: BEAR
LLY is showing clear technical deterioration after failing to sustain momentum near its 52-week high, with a bearish MACD zero-cross on the 4-hour timeframe and declining RSI across all timeframes. The stock sits just above 1-day support at $1061.62, and with volume normal and short-term momentum breaking down (30m RSI at 41, price below both 30m SMAs), a breakdown through that support toward the 4h SMA50 at $1001 and the volume POC at $977 is the path of least resistance. The upcoming ADA Scientific Sessions (June 5-8) create a "buy the rumor, sell the news" risk for the GLP-1 complex, and LLY's stretched valuation (P/E 39.2, D/E 139%) leaves it vulnerable to a mean-reverting pullback in a neutral macro regime that offers no directional tailwind.
LLY is pulling back toward the 1day support at $1061.62 and 4h SMA20 at $1062.14, creating a defined retest entry ahead of multiple near-term catalysts. The completion of CVS Caremark PBM coverage for Zepbound (June 1) removes a key distribution headwind, while the ADA Scientific Sessions (June 5-8) featuring retatrutide data and BofA's $1,251 price target provide upside catalysts. With strong fundamental momentum (25.9% EPS beat, 35% margins, forward P/E compressing to 24.8x) and the stock still 7% below its 52-week high, this pullback to support offers a favorable risk-reward entry for a swing back toward the $1125-1130 zone.
No clear trading edge identified
Bull/Bear CompetitionBALANCED
LLY presents a compelling long opportunity driven by recent fundamental catalysts and a technical setup that favors a retest of its all-time highs. The company has secured full PBM coverage for Zepbound and Foundayo, its flagship GLP-1 drugs, which is expected to accelerate revenue growth and market penetration. Additionally, the $3.83 billion acquisition of three vaccine developers signals a strategic expansion into infectious diseases, diversifying LLY's portfolio beyond obesity and diabetes. Technically, LLY is trading near the lower end of its recent range, with key support at $1061.62 and a pullback to the 20-day SMA ($1062.14 on the 4h timeframe), offering a favorable entry point for a swing trade toward the $1149.10 resistance level.
LLY presents a compelling short opportunity due to its overextended technical position near all-time highs, weakening momentum, and lack of immediate catalysts to sustain further upside. The stock is trading at $1068.25, just 7% below its 52-week high of $1149.10, with RSI and MACD indicators on the 4-hour timeframe showing signs of exhaustion (RSI 54.80 and falling, MACD histogram negative and declining). The recent FDA approval of Foundayo and full PBM coverage for Zepbound and Foundayo have already been priced in, leaving limited near-term upside catalysts. Additionally, the stock's valuation remains stretched with a forward P/E of 24.8, and macroeconomic uncertainties, such as fluctuating Treasury yields above 4.5%, pose a risk to high-multiple stocks like LLY.